亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

湖北省康寶泰精細化工有限公司  

度他雄胺,匹維溴銨,乙基D環,替米沙坦,非洛地平,恩替卡韋,鹽酸異丙嗪,鹽酸苯海拉明,醋酸洗必泰,鹽酸洛哌丁胺,鹽酸米諾環素,吲哚美辛,聯苯芐唑,鹽酸達克羅寧,鹽酸氯丙那林,灰黃霉素,氯霉素,馬來酸桂哌齊特,阿卡波糖,巖藻黃質,氨苯蝶啶,唑尼沙胺,莫西沙星母核,莫西沙星側鏈,鹽酸莫西沙星,丙酸氯倍他索,氨甲環酸,熊去氧膽酸,雷洛昔芬主鏈,雷洛昔芬側鏈

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:鮮經理
  • 電話:027-87738651
  • 郵件:hbkbtsales@163.com
  • 傳真:027-87738652
  • QQ:2572774575
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 華法林鈉,華法令鈉,酮芐香豆素鈉
華法林鈉,華法令鈉,酮芐香豆素鈉
單價 面議對比
詢價 暫無
發貨 湖北武漢市付款后3天內
品牌 華法林鈉
型號 129-06-6
規格 華法林鈉
過期 長期有效
更新 2011-12-16 15:33
 
詳細信息

華法林鈉

中文名稱: 華法林鈉
中文同義詞: 華法林鈉,華法令鈉,酮芐香豆素鈉,129-06-6;3-(3-氧代-1-苯基丁基)-4-羥基-2H-1-苯并吡喃二酮鈉鹽與異丙醇;3-(3-氧代-1-苯基丁基)-4-羥基-2H-1-苯并吡喃-2-酮鈉鹽
英文名稱: Warfarin sodium
CAS號: 129-06-6
分子式: C19H15O4.Na
分子量: 330.31
EINECS號: 204-929-4
用途: 用作抗凝血藥

©2025 湖北省康寶泰精細化工有限公司 版權所有   技術支持:化工網   訪問量:32211  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |